A clinical, diagnostic, and ecologic perspective on human anaplasmosis in the upper Midwest

Wisconsin Medical Journal

Volumn 113, Issue 3, 2014, Pages 107-114

  Schotthoefer, Anna M ^a   Meece, Jennifer K ^a   Fritsche, Thomas R ^a,b  

^a MARSHFIELD CLINIC   (United States)

^b UNIVERSITY OF WISCONSIN LA CROSSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; RNA 16S;

ANAPLASMA PHAGOCYTOPHILUM; DISEASE SURVEILLANCE; HEADACHE; HUMAN; HUMAN GRANULOCYTIC ANAPLASMOSIS; HUMAN MONOCYTIC EHRLICHIOSIS; IMMUNOFLUORESCENCE TEST; INCIDENCE; LEUKOPENIA; MIXED INFECTION; NONHUMAN; OPPORTUNISTIC INFECTION; PHYLOGENY; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; THROMBOCYTOPENIA; TICK BORNE DISEASE;

ANAPLASMOSIS; ANIMALS; EHRLICHIOSIS; HUMANS; MINNESOTA; POPULATION SURVEILLANCE; PREVALENCE; WISCONSIN;

EID: 84903317553     PISSN: 10981861     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Chen SM, Dumler JS, Bakken JS, Walker DH. Identification of a granulocytotropic Ehrlichia species as the etiologic agent of human disease. J Clin Microbiol.1994;32(3):589-595.
2. Dumler JS, Bakken JS. Human granulocytic ehrlichiosis in Wisconsin and Minnesota: a frequent infection with the potential for persistence. J Infect Dis. 1996;173(4):1027-1030.
3. Bakken JS, Goellner P, Van Etten M, et al. Seroprevalence of human granulocytic ehrlichioisis among permanent residents of northwestern Wisconsin. Clin Infect Dis. 1998;27(6):1491-1496.
4. Belongia EA, Reed KD, Mitchell PD, et al. Tickborne infections as a cause of nonspecific febrile illness in Wisconsin. Clin Infect Dis. 2001;32(10):1434-1439.
5. Bakken JS, Krueth J, Wilson-Nordskog C, Tilden RL, Asanovich K, Dumler JS. Clinical and laboratory characteristics of human granulocytic ehrlichioisis. JAMA. 1996;275(3):199-205.
6. Belongia EA, Gale CM, Reed KD, et al. Population-based incidence of human granulocytic ehrlichiosis in northwestern Wisconsin, 1997-1999. J Infect Dis. 2001;184(11):1470-1474.
7. Zhang S, Hai R, Li W, et al. Seroprevalence of human granulocytotropic anaplasmosis in central and southeastern China. Am J Trop Med Hyg. 2009;81(2):293-295.
8. Woldehiwet Z. The natural history of Anaplasma phagocytophilum. Vet Parasitol. 2010;167(2-4):108-122.
9. Centers for Disease Control and Prevention. Summary of Notifiable Diseases--United States, 2011. MMWR Morb Mortal Wkly Rep. 2013;60(53):1-117.
10. Dumler JS, Barbet AF, Bekker CP, et al. Reorganization of genera in the families Rickettsiaceae and Anaplasmataceae in the order Rickettsiales: unification of some species of Ehrlichia with Anaplasma, Cowdria with Ehrlichia and Ehrlichia with Neorickettsia, descriptions of six new species combinations and designation of Ehrlichia equi and 'HGE agent' as subjective synonyms of Ehrlichia phagocytophila. Int J Syst Evol Microbiol. 2001;51(Pt 6):2145-2165.
11. Natonal Notifiable Diseases Surveillance System. Ehrlichiosis and Anaplasmosis, 2008 Case Definition. http://wwwn.cdc.gov/NNDSS/script/casedef.aspx?CondYrID=667&Date Pub=1/1/2008. Accessed April 28, 2014.
12. Lee X, Hardy K, Johnson DH, Paskewitz SM. Hunter-killed deer surveillance to assess changes in the prevalence and distribution of Ixodes scapularis (Acari: Ixodidae) in Wisconsin. J Med Entomol. 2013;50(3):632-639.
13. Neitzel D, Kemperman MM. Tick-borne diseases in Minnesota: an update. Minn Med. 2012; 95(8):41-44.
14. Swanson SJ, Neitzel D, Reed KD, Belongia EA. Coinfections acquired from Ixodes ticks. Clin Microbiol Rev. 2006;19(4):708-727.
15. Pritt BS, Sloan LM, Johnson DK, et al. Emergence of a new pathogenic Ehrlichia species, Wisconsin and Minnesota, 2009. N Engl J Med. 2011;365(5):422-429.
16. Dumler JS, Madigan JE, Pusterla N, Bakken JS. Ehrlichioses in humans: epidemiology, clinical presentation, diagnosis, and treatment. Clin Infect Dis. 2007;45(Suppl 1):S45-51.
17. Thomas RJ, Dumler JS, Carlyon JA. Current management of human granulocytic anaplasmosis, human monocytic ehrlichiosis and Ehrlichia ewingii ehrlichiosis. Expert Rev Anti Infect Ther. 2009;7(6):709-722.
18. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006;43(9):1089-1134.
19. Telford SR 3rd, Dawson JE, Katavolos P, Warner CK, Kolbert CP, Persing DH. Perpetuation of the agent of human granulocytic ehrlichiosis in a deer tick-rodent cycle. Proc Natl Acad Sci USA. 1996;93(12):6209-6214.
20. Keesing F, Hersh MH, Tibbetts M, et al. Reservoir competence of vertebrate hosts for Anaplasma phagocytophilum. Emerg Infect Dis. 2012;18(12):2013-2016.
21. Levin ML, Nicholson WL, Massung RF, Sumner JW, Fish D. Comparison of the reservoir competence of medium-sized mammals and Peromyscus leucopus for Anaplasma phagocytophilum in Connecticut. Vector Borne Zoonotic Dis. 2002;2(3):125-136.
22. Dugan VG, Yabsley MJ, Tate CM, et al. Evaluation of white-tailed deer (Odocoileus virginianus) as natural sentinels for Anaplasma phagocytophilum. Vector Borne Zoonotic Dis. 2006;6(2):192-207.
23. Foley JE, Nieto NC, Massung R, Barbet A, Madigan J, Brown RN. Distinct ecologically relevant strains of Anaplasma phagocytophilum. Emerg Infect Dis. 2009;15(5):842-843.
24. Scharf W, Schauer S, Freyburger F, et al. Distinct host species correlate with Anaplasma phagocytophilum ankA gene clusters. J Clin Microbiol. 2011;49(3):790-796.
25. Massung RF, Mauel MJ, Owens JH, et al. Genetic variants of Ehrlichia phagocytophila, Rhode Island and Connecticut. Emerg Infect Dis. 2002;8(5):467-472.
26. Massung RF, Priestley RA, Miller NJ, Mather TN, Levin ML: Inability of a variant strain of Anaplasma phagocytophilum to infect mice. J Infect Dis. 2003;188(11):1757-1763.
27. Morissette E, Massung RF, Foley JE, Alleman AR, Foley P, Barbet AF. Diversity of Anaplasma phagocytophilum strains, USA. Emerg Infect Dis. 2009;15(6):928-931.
28. Belongia EA, Reed KD, Mitchell PD, et al. Prevalence of granulocytic Ehrlichia infection among white-tailed deer in Wisconsin. J Clin Microbiol. 1997;35(6):1465-1468.
29. Michalski M, Rosenfield C, Erickson M, et al. Anaplasma phagocytophilum in central and western Wisconsin: a molecular survey. Parasitol Res. 2006;99(6):694-699.
30. Baldridge GD, Scoles GA, Burkhardt NY, Schloeder B, Kurtti TJ, Munderloh UG. Transovarial transmission of Francisella-like endosymbionts and Anaplasma phagocytophilum variants in Dermacentor albipictus (Acari: Ixodidae). J Med Entomol. 2009;46(3):625-632.
31. Johnson RC, Kodner C, Jarnefeld J, Eck DK, Xu Y. Agents of Human Anaplasmosis and Lyme Disease at Camp Ripley, Minnesota. Vector Borne Zoonotic Dis. 2011;11(12): 1529-1534.
32. Bullock PM, Ames TR, Robinson RA, Greig B, Mellencamp MA, Dumler JS. Ehrlichia equi infection of horses from Minnesota and Wisconsin: detection of seroconversion and acute disease investigation. J Vet Intern Med. 2000;14(3):252-257.
33. Nicholson WL, Allen KE, McQuiston JH, Breitschwerdt EB, Little SE. The increasing recognition of rickettsial pathogens in dogs and people. Trends Parasitol. 2010;26(4):205-212.
34. Bowman D, Little SE, Lorentzen L, Shields J, Sullivan MP, Carlin EP. Prevalence and geographic distribution of Dirofilaria immitis, Borrelia burgdorferi, Ehrlichia canis, and Anaplasma phagocytophilum in dogs in the United States: results of a national clinic-based serologic survey. Vet Parasitol. 2009;160(1-2):138-148.
35. Pancholi P, Kolbert C P, Mitchell PD, et al. Ixodes dammini as a potential vector of human granulocytic ehrlichiosis. J Infect Dis. 1995;172(4):1007-1012.
36. Steiner FE, Pinger RR, Vann CN, et al. Infection and co-infection rates of Anaplasma phagocytophilum variants, Babesia spp., Borrelia burgdorferi, and the rickettsial endosymbiont in Ixodes scapularis (Acari: Ixodidae) from sites in Indiana, Maine, Pennsylvania, and Wisconsin. J Med Entomol. 2008;45(2):289-297.
37. Lovrich SD, Jobe DA, Kowalski TJ, Policepatil SM, Callister SM. Expansion of the Midwestern focus for Human granulocytic anaplasmosis into the region surrounding La Crosse, Wisconsin. J Clin Microbiol. 2011;49(11): 3855-3859.
38. Katavolos P, Armstrong PM, Dawson JE, Telford SR. Duration of tick attachment required for transmission of granulocytic ehrlichiosis. J Infect Dis. 1998;177(5):1422-1425.
39. des Vignes F, Piesman J, Heffernan R, Schulze TL, Stafford KC, Fish D. Effect of tick removal on transmission of Borrelia burgdorferi and Ehrlichia phagocytophila by Ixodes scapularis nymphs. J Infect Dis. 2001;183(5):773-778.
40. Bakken JS, Dumler JS. Human granulocytic ehrlichiosis. Clin Infect Dis. 2000;31(2):554-560.
41. Schotthoefer AM, Meece JK, Ivacic LC, et al. Comparison of a real-time PCR method with serology and blood smear analysis for diagnosis of human anaplasmosis: importance of infection time course for optimal test utilization. J Clin Microbiol. 2013;51(7):2147-2153.
42. Dahlgren FS, Mandel EJ, Krebs JW, Massung RF, McQuiston JH. Increasing incidence of Ehrlichia chaffeensis and Anaplasma phagocytophilum in the United States, 2000-2007. Am J Trop Med Hyg. 2011;85(1):124-131.
43. Talsness SR, Shukla SK, Mazza JJ, Yale SH. Rhabdomyolysis-induced acute kidney injury secondary to Anaplasma phagocytophilum and concomitant statin use. WMJ. 2011;110(2):82-84.
44. Belongia EA, Reed KD, Mitchell PD, et al. Clinical and epidemiological features of early Lyme disease and human granulocytic ehrlichiosis in Wisconsin. Clin Infect Dis. 1999;29(6):1472-1477.
45. Wormser GP, Aguero-Rosenfeld ME, Cox ME, et al. Differences and similarities between culture-confirmed human granulocytic anaplasmosis and early lyme disease. J Clin Microbiol. 2013;51(3):954-958.
46. Mitchell PD, Reed KD, Hofkes JM. Immunoserologic evidence of coinfection with Borrelia burgdorferi, Babesia microti, and human granulocytic Ehrlichia species in residents of Wisconsin and Minnesota. J Clin Microbiol. 1996;34(3):724-727.
47. Chapman AS, Bakken JS, Folk SM, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever, ehrlichioses, and anaplasmosis- United States: a practical guide for physicians and other health-care and public health professionals. MMWR Recomm Rep. 2006;55(RR-4):1-27.
48. Ramsey AH, Belongia EA, Gale CM, Davis JP. Outcomes of treated human granulocytic ehrlichiosis cases. Emerg Infect Dis. 2002;8(4):398-401.
49. Bakken JS, Haller I, Riddell D, Walls JJ, Dumler JS. The serological response of patients infected with the agent of human granulocytic ehrlichiosis. Clin Infect Dis. 2002;34(1):22-27.
50. Dumler JS, Brouqui P. Molecular diagnosis of human granulocytic anaplasmosis. Expert Rev Mol Diagn. 2004;4(4):559-569.
51. Bell CA, Patel R. A real-time combined polymerase chain reaction assay for the rapid detection and differentiation of Anaplasma phagocytophilum, Ehrlichia chaffeensis, and Ehrlichia ewingii. Diagn Microbiol Infect Dis. 2005;53(4):301-306.
52. Massung RF, Slater KG. Comparison of PCR assays for detection of the agent of human granulocytic ehrlichiosis, Anaplasma phagocytophilum. J Clin Microbiol. 2003;41(2):717-722.
53. Walls JJ, Caturegli P, Bakken JS, Asanovich KM, Dumler JS. Improved sensitivity of PCR for diagnosis of human granulocytic ehrlichiosis using epank1 genes of Ehrlichia phagocytophila-group ehrlichiae. J Clin Microbiol. 2000;38(1):354-356.
54. Piesman J, Eisen L. Prevention of tick-borne diseases. Annu Rev Entomol. 2008;53:323-343.
55. Eisen L, Eisen RJ. Using Geographic Information Systems and Decision Support Systems for the prediction, prevention, and control of vector-borne diseases. Annu Rev Entomol. 2001;56:41-61.
56. Eisen L, Eisen RJ. Need for improved methods to collect and present spatial epidemiologic data for vectorborne diseases. Emerg Infect Dis. 2007;13(12):1816-1820.
57. Dunning Hotopp JC, Lin M, Madupu R, et al. Comparative genomics of emerging human ehrlichiosis agents. PLoS Genet. 2006;2:e21.
58. de la Fuente J, Kocan KM, Blouin EF, et al. Functional genomics and evolution of tick-Anaplasma interactions and vaccine development. Vet Parasitol. 2010;167(2-4):175-186.